UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
_________________
Date of Report (Date of earliest event reported): June 26, 2018
Alliqua BioMedical, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware |
001-36278 |
58-2349413 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) | ||
|
2150 Cabot Blvd., West Suite B Langhorne, PA |
19047 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (215) 702-8550
1010 Stony Hill Road
Suite 200
Yardley, Pennsylvania 19067
| Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On June 26, 2018, Alliqua BioMedical, Inc. (the “Company”) held its 2018 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the following two proposals were submitted to the Company’s stockholders:
| (1) |
Election of five directors to serve on the Company’s board of directors for a term of one year or until their respective successors are elected and qualified, for which the following were nominees: David Johnson, Mark Wagner, Joseph Leone, Gary Restani and Jeffrey Sklar. |
| (2) | Ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018. |
For more information about the foregoing proposals, see the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on May 17, 2018, the relevant portions of which are incorporated herein by reference. Holders of the Company's common stock were entitled to one vote per share of common stock. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below.
| (1) | Election of five directors to serve on the Company’s board of directors for a term of one year or until their respective successors are elected and qualified: |
|
Director |
For | Withheld | Broker Non-Votes | |||
| David Johnson | 2,252,151 | 47,528 | 1,649,467 | |||
| Joseph Leone | 2,247,958 | 51,721 | 1,649,467 | |||
| Gary Restani | 2,136,657 | 163,022 | 1,649,467 | |||
| Jeffrey Sklar | 2,136,637 | 163,042 | 1,649,467 | |||
| Mark Wagner | 2,137,657 | 162,022 | 1,649,467 |
| (2) | Ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018: |
| For | Against | Abstain | ||
| 3,805,873 | 108,100 | 35,173 |
The results reported above are final voting results. No other matters were considered or voted upon at the meeting.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALLIQUA BIOMEDICAL, INC. | ||
| Dated: June 26, 2018 | By: | /s/ Joseph Warusz |
| Name: Joseph Warusz | ||
| Title: Chief Financial Officer | ||